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POPULATION GENETICS
Population Genetics of Cryptosporidium parvum
Research on the population genetics of Cryptosporidium
parvum is showing exciting developments. A study of
numerous C. parvum isolates of human and animal origin
collected in a small area of Scotland has uncovered differ-
ences in the epidemiology of what was originally referred
to as C. parvum type 1 (also, anthroponotic type) and type
2 (zoonotic type), a designation recently changed to C.
hominis and C. parvum. This study, based on fingerprints
obtained from eight polymorphic genetic markers, showed
striking differences between the population structure of
these species; a clonal C. hominis population and a more
complex C. parvum population. The population structure of
C. hominis was consistent with the epidemic nature of
human infections, where a small number of genotypes pre-
dominate. In contrast, C. parvum (type 2) genetic finger-
prints showed evidence of random mating among geneti-
cally diverse parasites.  Evidence for partitioning of the
species according to host (human and bovine) was also
inferred from these data. Two questions we are left with are
whether these observations are specific to this particular
location, where human transmission is relatively infre-
quent, and whether regions with high prevalence of human
cryptosporidiosis will show more complex structures in
both species. If substructuring into human– and bovine–
derived C. parvum (type 2) is consistently observed, the
potential for zoonotic transmission of C. parvum may also
have to be reexamined.
Widmer G. Population genetics of Cryptosporidium parvum. Trends
Parasitol 2004;20:3–6;discussion 6. Available at: http://dx.doi.org/
10.1016/j.pt.2003.10.010
DIAGNOSTIC VIROLOGY
Role for Arrays in Clinical Virology: Fact or Fiction?
Polymerase chain reaction (PCR) detection of genomic
DNA or RNA has become an indispensable tool for the
diagnosis and surveillance of viral disease. Perhaps the
biggest drawback of PCR, though, is that only one or a few
viruses can be searched for in a single test. DNA chips or
microarrays have the potential to overcome this disadvan-
tage and can provide a near-patient test that identifies both
known viruses and those causing newly emerging diseases
such as SARS. For this potential to be realized, however,
the PCR techniques capable of amplifying any adventi-
tious sequence in a clinical specimen and the microarray-
ing hybridization and detection technologies necessary for
obtaining rapid and reproducible results need to converge.
The arrays that have already been developed for use in
virology point the way forward.
Clewley JP. A role for arrays in clinical virology: fact or fiction? J
Clin Virol 2004; 29:2–12. Review. Available at: http://dx.doi.org/
10.1016/j.jcv.2003.08.002
MOLECULAR EPIDEMIOLOGY
Multilocus Sequence Typing and the Evolution of
Methicillin-resistant Staphylococcus aureus
Methicillin-resistant  Staphylococcus aureus (MRSA)
continue to adapt to the selective pressure of antimicrobial
agents and to exploit new niches, as evidenced by the
recent isolation of strains with high-level vancomycin
resistance and the emergence of MRSA as a community
pathogen. The combined use of the bacterial genotyping
technique, multilocus sequence typing (MLST), and char-
acterization of the mobile methicillin-resistance determi-
nant, staphylococcal chromosomal cassette mec
(SCCmec), has provided new insights into MRSA strain
nomenclature, evolution, and epidemiology.  The first
MRSA emerged when SCCmec was acquired by an epi-
demic methicillin-susceptible strain prevalent in Europe.
Acquisition of SCCmec by other successful strains has led
to the emergence of at least 11 major epidemic MRSA
strains belonging to five distinct lineages with a global
geographic distribution. These five lineages have evolved
both hospital-acquired and community-acquired MRSA,
but some of the newly emerging community strains
descend from other lineages.
Robinson DA, Enright MC. Multilocus sequence typing and the evo-
lution of methicillin-resistant Staphylococcus aureus. Clin Microbiol
Infect 2004;10:92–7. 
VACCINES
Mimicking Live Flavivirus Immunization 
with a Noninfectious RNA Vaccine
A new genetic vaccine against flaviviruses is presented
that can stimulate a comprehensive immune response sim-
ilar to a live vaccine but with the safety profile of an inac-
tivated vaccine. The principle is based on the use of nonin-
fectious but replication-competent genomic RNA. This
vaccine mimics live viral infection, although there is no
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spread of virus in the body. The complete replication com-
plex is expressed, including all  viral nonstructural proteins
known to be targets of the humoral and cellular immune
response. In addition, subviral particles consisting of the
viral surface proteins prM/M and E are produced and pre-
sented to the immune system. The proof-of-principle is
demonstrated with tick-borne encephalitis virus (TBEV).
Because of the close genetic relationship among members
of the genus Flavivirus, this principle presumably can also
be applied to other pathogens of worldwide medical
importance, such as dengue viruses, Japanese encephalitis
virus, yellow fever virus, and West Nile virus. The vaccine
consists of in vitro synthesized genomic RNA, genetically
modified to abolish viral infectivity but to provide ample
production and release of subviral particles. Gene-gun
mediated injection of this experimental TBEV vaccine into
adult mice is shown to yield a neutralizing and protective
immune response. 
Koffler RM, Aberle JH, Aberle SW, Allison SL, Heinz FX, Mandl
CW. Mimicking live flavivirus immunization with a non-infectious
RNA vaccine. Proc Natl Acad Sci U S A 2004;101:1951–6. Epub
2004 Feb 09. Available at: www.pnas.org/cgi/content/abstract/
101/7/1951
ECOLOGY
Bacterial Biofilms: Prokaryotic Adventures 
in Multicellularity 
Three-dimensional bacterial biofilm microstructures
display multicellular characteristics in common with high-
er organisms, such as cell death and differentiation during
development, which carry several medical and evolution-
ary implications. Biofilm microstructures appear to
enhance bacterial tolerance to a number of stresses, includ-
ing antimicrobial agents; determinants of multicellularity,
such as cell-cell signaling, are necessary for this tolerance.
Processes of microcolony development and differentiation
are therefore of particular interest as targets for novel
strategies to control biofilms.
Webb JS, Givskov M, Kjelleberg S. Bacterial biofilms: prokaryotic
adventures in multicellularity. Curr Opin Microbiol 2003;6:578–85.
Review. Available at: http://dx.doi.org/10.1016/j.mib.2003.10.014 
PATHOGENESIS
CCR5 and CXCR4 Co-Receptors in HIV Infection 
This article examined the central role played by co-
receptor expression and usage in the transmission and
pathogenic effects of HIV-1 infection of humans. The
review contains a discussion of the HIV-1 phenotypic vari-
ants defined by their use of the CCR5 or CXCR4 co-recep-
tors. How the different cellular tropism patterns of these
viral variants influence how and where HIV-1 replicates in
vivo is also discussed, with emphasis on the thymus and
gut-associated lymphoid tissues. The review also contains
a consideration of the possible outcomes of the use of co-
receptor antagonists as drugs to treat HIV-1 infection in
vivo.
Moore JP, Kitchen SG, Pugach P, Zack, JA. The CCR5 and CXCR4
coreceptors—central to understanding the transmission and patho-
genesis of human immunodeficiency virus type 1 infection. AIDS
Res Hum Retroviruses 2004;20:111–26. 
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